Free Newsletter
Drug shortages fuel big pharma suspicions
Drug shortages in Canada--primarily of generics but also brand name treatments---are stimulating bad-pharma thinking. Supply shortfalls in Ontario and elsewhere are proving extensive enough to feed conspiracy theorists.
Generics-makers, for their part, cite manufacturing and supply glitches, as well as a more stringent regulatory environment. The Canadian Generic Pharmaceutical Association says worldwide shortages of active ingredients, shutdowns at major manufacturers and production changes are driving the shortfall.
Such scant explanations for the shortages compound the distrust. Some patients and pharmacists speculate that manufacturers are foregoing certain generics because of government programs that reduce their pricing, reports the National Post. Others believe that older, cheaper drugs are being abandoned as drugmakers shift their efforts to newer, more profitable products.
South of the border, the FDA tallies U.S. drug shortages on its website. Some 40 products are listed currently. Reasons most often cited are manufacturing delays and demand increases.
- see the article
Related Article:
Anesthesia drug drought hits prisons, people, pets
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: